Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
28.39
-0.37 (-1.29%)
Oct 30, 2026, 4:00 PM EST - Market closed
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $1.00M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $1.00M, down -93.33% year-over-year. In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth. That makes Zenas BioPharma the 43,631st largest company in the world by revenue and 6,111th in the United States.
Revenue (ttm)
$1.00M
Revenue Growth
-93.33%
P/S Ratio
1,850.37
Revenue / Employee
$5,988
Employees
167
Market Cap
1.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
ZBIO News
- 5 days ago - Citi adds ‘upside 90-day catalyst watch’ on Zenas BioPharma - TheFly
- 6 days ago - Zenas BioPharma Transcript: Investor update - Transcripts
- 6 days ago - Zenas BioPharma Slides: Investor update - Filings
- 16 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 21 days ago - Zenas BioPharma presents new obexelimab data - TheFly
- 26 days ago - Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 - GlobeNewsWire
- 27 days ago - Zenas BioPharma to Host Virtual R&D Event - GlobeNewsWire